Insmed Q4 Earnings Call Highlights
View original at finance.yahoo.comInsmed Q4 Earnings Call Highlights Insmed logo Key Points Insmed reported BRINSUPRI net revenue of $144.6 million in its first full quarter and guided 2026 BRINSUPRI sales of at least $1 billion, saying total 2026 revenue should be more than double 2025 and reiterating a potential peak above $5 billion for the bronchie…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Could begin to see COPD/asthma overlap patients as early as end of this year in existing pulmonary practices, with more evident impact in 2027 and beyond
80% confidenceBRINSUPRI Q4 net revenue of $144.6 million exceeded internal expectations
80% confidence2026 ARIKAYCE gross-to-net expected to be low- to mid-20s, slightly higher than 2025 due primarily to IRA-related impacts
80% confidenceCompany can reach cash flow positivity without raising additional capital
80% confidenceTPIP may be clinically superior and could represent a major contribution to patient care versus existing treprostinil options
80% confidence2025 was an exceptional year for Insmed
80% confidenceU.S. diagnosed non-CF bronchiectasis population is roughly 500,000 patients, with about 250,000 estimated to have had two or more exacerbations in prior 12 months
80% confidenceTPIP was significantly de-risked by 2025 clinical data
80% confidenceTotal 2026 revenue expected to be more than double 2025 levels when combining BRINSUPRI with ARIKAYCE
80% confidenceINS1148 has DPP1-like potential across multiple diseases
80% confidenceBRINSUPRI could exceed peak sales estimate above $5 billion for bronchiectasis opportunity
80% confidenceOver 90% of targeted patient lives have access to BRINSUPRI reimbursement either via documented payer policy or medical exception
80% confidenceAmong roughly 4,000 physicians who wrote a prescription through end of 2025, nearly half prescribed BRINSUPRI to only one patient
80% confidenceInternal dashboards show adherence and discontinuation metrics at or above targets
80% confidenceJapan ARIKAYCE sales grew 40% versus 2024 and accounted for more than a quarter of global ARIKAYCE revenues
80% confidenceBRINSUPRI early launch trajectory is strongly up and to the right
80% confidenceBronchiectasis could be involved in 30% to over 50% of patients with moderate to severe COPD and 25% to 40% of patients with severe asthma
80% confidenceFDA feedback indicated a single Phase III trial could be sufficient for registrational submission in PAH if successful
80% confidenceENCORE trial success could expand ARIKAYCE addressable market from around 30,000 patients to more than 200,000
80% confidence2026 BRINSUPRI gross-to-net expected in mid-20s to low-30s range
80% confidence